Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02009436 · ClinicalTrials.gov registry record · Phase 1
Azacitidine in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
A Phase 1 study, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02009436 is a Phase 1 study that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 8 participants.
The verdict
NCT02009436, a Phase 1 study, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This pilot phase I trial studies the side effects and best dose of azacitidine in treating patients with lung cancer that is stage IV or has returned after previous treatments (recurrent). Azacitidine is a drug used in chemotherapy that may stop tumor cells from growing or spreading by activating genes that help prevent cancer growth, called tumor suppressor genes. As people age, these genes are silenced by a chemical reaction that occurs naturally in the body, or by exposure to environmental factors such as smoking. Azacitidine may help reverse this process and restore the function of the tumor suppressor genes. Delivering azacitidine directly into the lungs by inhalation may work better in treating lung cancer.
Interventions
- DRUG Azacitidine
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-02-09 |
| Est. Completion | 2018-07-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02009436
The ClinicalTrials.gov registry entry for NCT02009436 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Azacitidine is the first listed.
NCT02009436 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02009436 about?
NCT02009436 is a clinical study titled "Azacitidine in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer". This pilot phase I trial studies the side effects and best dose of azacitidine in treating patients with lung cancer that is stage IV or has returned after previous treatments (recurrent). Azacitidine is a drug used in chemotherapy that may stop tumor cells from growing or spreading by activating ge...
What is the current status of trial NCT02009436?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2015-02-09. Estimated completion is 2018-07-18.
What interventions are being tested in trial NCT02009436?
The interventions under investigation include: Azacitidine (DRUG), Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT02009436?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.